Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants

被引:0
作者
Steven J. Smith
Gary T. Pauly
Aamir Akram
Kevin Melody
Ganesha Rai
David J. Maloney
Zandrea Ambrose
Craig J. Thomas
Joel T. Schneider
Stephen H. Hughes
机构
[1] National Institutes of Health,HIV Drug Resistance Program, National Cancer Institute
[2] National Institutes of Health,Frederick
[3] University of Pittsburgh,Chemical Biology Laboratory, National Cancer Institute
[4] University of Pittsburgh,Frederick
[5] NIH,Department of Infectious Diseases and Microbiology, Graduate School of Public Health
来源
Retrovirology | / 13卷
关键词
HIV-1; Nonnucleoside reverse transcriptase inhibitors; Rilpivirine; Antiviral activity; Resistance; Analogs; Susceptibility; Binding pocket; Doravirine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 258 条
[21]  
Pauwels R(2012)A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants Retrovirology 9 99-10032
[22]  
Janssen PA(2001)The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance J Mol Biol 309 437-418
[23]  
Boyer PL(1999)Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids Proc Natl Acad Sci USA 96 10027-2737
[24]  
Clark P(2000)The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase J Mol Biol 300 403-38123
[25]  
Smith RH(2011)Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket J Med Chem 54 2727-128
[26]  
Kroeger Smith MB(2012)Biochemical mechanism of HIV-1 resistance to rilpivirine J Biol Chem 287 38110-1471
[27]  
Michejda CJ(2013)HIV-1 reverse transcriptase and antiviral drug resistance. Part 2 Curr Opin Virol 3 119-1335
[28]  
Hughes SH(2008)High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc Natl Acad Sci USA 105 1466-39
[29]  
Arnold E(2011)Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JAMA 305 1327-341
[30]  
Hsiou Y(2014)A review of the toxicity of HIV medications J Med Toxicol 10 26-259